Antibody Startup Adagio Raises $336 Million To Develop A Variant-Proof Treatment For Covid-19

Retrieved on: 2021-04-19 10:30:00

Tags for this article:

Click the tags to see associated articles and topics

Antibody Startup Adagio Raises $336 Million To Develop A Variant-Proof Treatment For Covid-19. View article details on hiswai:

Excerpt

While many biotech companies are obsessed with making a vaccine, Gerngross' company Adagio is going all-in on the promise of monoclonal ...

Article found on: www.forbes.com